<DOC>
	<DOCNO>NCT00954993</DOCNO>
	<brief_summary>This study evaluate hepatic ( liver ) plasma pharmacokinetics Vaniprevir ( MK-7009 ) evaluation ribonucleic acid ( RNA ) hepatitis C virus ( HCV ) genotype 1 , HCV-infected participant .</brief_summary>
	<brief_title>Pharmacokinetics Vaniprevir ( MK-7009 ) Hepatitis C Virus RNA Levels After Vaniprevir Treatment ( MK-7009-029 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Participant male female 40 65 year age prestudy ( screen ) visit Participant Body Mass Index ( BMI ) ≥18.5 kg/m2 ≤36.0 kg/m2 . Participant require diagnostic biopsy , per local treatment guideline , monitor progression liver disease . Participant chronic compensate , genotype 1 HCV infection define positive serology HCV detectable HCV RNA peripheral blood Participant meet prespecified criterion base laboratory value screen follow : Alanine aminotransferase ( ALT ) : ≤400 U/L Aspartate aminotransferase ( AST ) : ≤400 U/L Total bilirubin : ≤2.4 mg/dL Direct bilirubin : ≤1.0 mg/dL Creatinine clearance ( Clcr ) : ≥60 mL/min ( CockcroftGault equation* ) Albumin : ≥3.3 g/dL Alkaline phosphatase : ≤260 U/L Hemoglobin : ≥13 g/dL ( men ) , ≥12 g/dL ( woman ) White blood cell count : 3.8 10.7 ×103/μL Absolute neutrophil count : ≥1.5 ×103/μL Platelet count : ≥120 ×103/μL International normalize ratio ( INR ) : ≤1.2 Thyroid stimulate hormone ( TSH ) : 0.34 5.60 μIU/mL Alpha fetoprotein ( AFP ) : &lt; 100 ng/mL Participant cirrhosis confirm FibroSure™/FibroTest® Participant treatmentexperienced , regard prior treatment chronic HCV infection Participant ability avoid use anticoagulant , nonsteroidal antiinflammatory agent aspirin least five ( 5 ) day precede initial liver biopsy continue throughout entire study Participant age legal consent , mentally legally incapacitated/ institutionalize , significant emotional problem time prestudy screen visit expect conduct study history clinically significant psychiatric disorder , opinion investigator , would interfere study procedure . Participant history stroke , chronic seizure , major neurological disorder Participant achieve viral response prior treatment license interferonbased therapy ( i.e. , 'null responder ' ) . Viral response define &gt; = 2log^10 decline HCV viral RNA within first 12 week therapy . Participant previously treat NS3/4A protease inhibitor chronic HCV infection Evidence high grade bridge fibrosis ( eg , METAVIR score &gt; 3 , Ishak score &gt; 4 Scheuer score &gt; 3 ) prior liver biopsy within 3 year study entry Participant evidence history chronic hepatitis cause HCV include limited nonHCV viral hepatitis , nonalcoholic steatohepatitis ( NASH ) , druginduced hepatitis autoimmune hepatitis . Note : Participants history acute nonHCVrelated hepatitis resolve &gt; 6 month study entry enrol . Participant clinical laboratory evidence cirrhosis advance liver disease Participant decompensated liver disease indicate history ascites , hepatic encephalopathy , bleed esophageal varix Participant diagnose suspect hepatocellular carcinoma Participant coinfection human immunodeficiency virus ( HIV ) Participant positive Hepatitis B surface antigen evidence active Hepatitis B infection Participant history gastric bypass surgery , bowel resection disorder opinion investigator may interfere absorption study medication Participant history clinically significant uncontrolled endocrine , gastrointestinal , cardiovascular , hematological , immunological , renal , respiratory , genitourinary abnormality diseases Participant history neoplastic disease ( include leukemia , lymphoma , malignant melanoma ) , myeloproliferative disease , regardless time since treatment Participant consume excessive amount alcohol , define great 3 glass alcoholic beverage ( 1 glass approximately equivalent : beer [ 284 mL ] , wine [ 125 mL ] , distilled spirit [ 25 mL ] ) per day Participant currently regular user ( include use illicit drug history drug ( include alcohol ) abuse within last 3 month Female participant pregnant , lactating , expect conceive donate egg , childbearing potential unwilling commit two method birth control outline inclusion criterion Male Participant plan impregnate provide sperm donation female sexual partner childbearing potential unwilling commit use two method birth control outline inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatitis C Virus ( HCV )</keyword>
	<keyword>Vaniprevir</keyword>
	<keyword>MK-7009</keyword>
</DOC>